Neurocognitive impairment in schizophrenia and how it affects treatment options.
OBJECTIVE
To review the roles played by neurocognitive assessment in the treatment of schizophrenia and in the design of treatment research strategies.


METHODS
A review of the literature and summaries of clinical and research implications are presented, with directions for future research.


RESULTS
Neurocognitive deficits are now targets of antipsychotic drug treatment and should increasingly be used to refine both theory and clinical practice by considering the effects of treatments at the level of neural systems.


CONCLUSIONS
Efforts to bridge the gaps between preclinical and clinical assessments should yield large rewards in drug development and individualized treatment strategies. Functional neuroimaging may play a major role in these developments.
Bilder
R M
RM
Hillside Hospital Division of Long Island Jewish Medical Center, Glen Oaks, New York. bilder@aecom.yu.edu
D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D001931:Brain Mapping; D003072:Cognition Disorders / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D009483:Neuropsychological Tests; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology; D012565:Schizophrenic Psychology; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D011954:Receptors, Dopamine